Active Investments

Interdict Bio

Private

Cavalry Biosciences

Private

Mahzi Therapeutics

Private

Ocelot Bio

Private

Iris Medicine

Private

Unity Biotechnology

Public (NASDAQ: UBX)

Alumni Investments

Corvidia

Acquired by Novo Nordisk

REGENXBIO

Public (NASDAQ: RGNX)

Spirox

Acquired by Entellus Medical

Camille Samuels Partner

Focus Areas: Biotechnology, Consumer Health, Medical Devices
Location: Palo Alto

Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Cavalry, Iris, Mahzi, Ocelot Bio, Unity (UBX), and XCaliber – and previously served on the board of several other Venrock companies including Corvidia (sold to Novo Nordisk), Spirox (acquired by Stryker via Entellus) and RegenXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she supported many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH/acq by Allergan), Novacardia (acq by Merck), and ParAllele (acq by Affymetrix). Before her venture career, Cami worked in business development at Tularik (acq by Amgen). During her early career, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.

Podcasts

Writing

News

Active Companies

Interdict Bio

A novel, small molecule therapeutics platform for addressing historically undruggable protein targets. 

Cavalry Biosciences

Reprogramming growth factors to treat rare disease.

Mahzi Therapeutics

Ocelot Bio

On a mission to revolutionize treatment options for patients with severe liver disease.

Iris Medicine

Unity Biotechnology

Alumni Companies

Corvidia

REGENXBIO

Spirox